Isobe Hirokazu, Takano Tomomi, Nishiyama Akihito, Hung Wei-Chun, Kuniyuki Shuichi, Shibuya Yasuhiro, Reva Ivan, Yabe Shizuka, Iwao Yasuhisa, Higuchi Wataru, Khokhlova Olga E, Okubo Takeshi, Yamamoto Tatsuo
Division of Bacteriology, Department of Infectious Disease Control and International Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Biomed Res. 2012 Apr;33(2):97-109. doi: 10.2220/biomedres.33.97.
Methicillin-resistant Staphylococcus aureus (MRSA) includes hospital-acquired MRSA (HAMRSA) and community-acquired MRSA (CA-MRSA). Panton-Valentine leukocidin (PVL)-positive multilocus sequence type 30 (ST30) MRSA is one of worldwide CA-MRSA, which has also persisted in Japan since the 1980s. However, unexpectedly, it was not the same ST30 clone throughout. Before 2000, it was HA-MRSA with spa43 and ψSa3sea (phage Sa3 carrying the sea gene) and only one PVL-positive MRSA in Japan; in the 1980s, ST30 MRSA accounted for 23.5% of HA-MRSA, showed multidrug resistance, had high MICs for oxacillin and imipenem, and caused decubitus and pneumonia in hospitalized patients. A dynamic clonal change (spa43/ψSa3sea→ spa19) occurred around 2000-2002. A rare spa43/ψSa3sea/SCCmecI-IE25923 genotype also emerged. After 2002, the prevalent spa19 clone was CA-MRSA; it accounted for only 0.3% (or less) of MRSA in hospitals but 7.6% of CA-MRSA. Since 2007, PVL-positive CA-MRSA with other ST types (such as ST8, ST22, and ST59) also emerged in Japan, albeit at a low frequency. ST30/spa19 CA-MRSA occasionally caused severe invasive infections and a novel ST1335/spa19 genotype emerged. These ST30/spa19 CA-MRSA and variants were identified by pulsed field gel electrophoresis. Further analysis revealed that PVL-positive ST30/spa19 CA-MRSA is a highlyvirulent, successful clone, having a potential of clonal expansion.
耐甲氧西林金黄色葡萄球菌(MRSA)包括医院获得性MRSA(HAMRSA)和社区获得性MRSA(CA-MRSA)。杀白细胞素(PVL)阳性的多位点序列分型30(ST30)MRSA是全球范围内的CA-MRSA之一,自20世纪80年代以来一直在日本存在。然而,出乎意料的是,它并非始终是同一个ST30克隆。2000年之前,它是带有spa43和ψSa3sea(携带sea基因的噬菌体Sa3)的HA-MRSA,且是日本唯一一株PVL阳性的MRSA;在20世纪80年代,ST30 MRSA占HA-MRSA的23.5%,表现出多重耐药性,对苯唑西林和亚胺培南的最低抑菌浓度较高,并在住院患者中引起褥疮和肺炎。2000年至2002年左右发生了动态克隆变化(spa43/ψSa3sea→spa19)。还出现了一种罕见的spa43/ψSa3sea/SCCmecI-IE25923基因型。2002年之后,流行的spa19克隆是CA-MRSA;它在医院的MRSA中仅占0.3%(或更低),但在CA-MRSA中占7.6%。自2007年以来,日本也出现了其他ST型(如ST8、ST22和ST59)的PVL阳性CA-MRSA,尽管频率较低。ST30/spa19 CA-MRSA偶尔会引起严重的侵袭性感染,并且出现了一种新的ST1335/spa19基因型。这些ST30/spa19 CA-MRSA及其变体通过脉冲场凝胶电泳进行了鉴定。进一步分析表明,PVL阳性的ST30/spa19 CA-MRSA是一种高毒力、成功的克隆,具有克隆扩张的潜力。